Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States.

Le QA, Hay JW, Becker R, Wang Y

The Annals of pharmacotherapy30 Aug 2018Cited by 26 (Europe PMC)

PMID30160186PMCIDPMC6311620DOI10.1177/1060028018798034PepBankPUB-30160186

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01Computer modelNot a test of Abaloparatide (Tymlos) aloneIn silicoOther
In simulated women with osteoporosis, ABL/ALN yielded $26 837 in discounted per-patient costs versus $46 783 with TPTD/ALN over a 10-year period.
In plain wordsIn osteoporosis simulations, ABL/ALN yielded lower costs than TPTD/ALN.
Peptide
Abaloparatide (Tymlos)
Outcome
DecreaseDiscounted cost
Study
n: not reported in source
Discrete-event simulation of sequential osteoporosis treatment
Comparator
TPTD/ALN
Outcome group
Cost-effectiveness · Pharmacology
Source sentences
Summary
Over a 10-year period, the DES model yielded average total discounted per-patient costs of $10 212, $46 783, and $26 837 and quality-adjusted life-years (QALYs) of 6.742, 6.781, and 6.792 for PBO/ALN, TPTD/ALN, and ABL/ALN, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
A discrete-event simulation (DES) model was developed to assess cost-effectiveness of ABL from the US health care perspective.
Summary · context
The model included three 18-month treatment strategies with either placebo (PBO), TPTD, or ABL, all followed by additional 5-year treatment with alendronate (ALN).
Summary · context
High-risk patients were defined as women with PMO ⩾65 years old with a prior vertebral fracture.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3016018601
02Computer modelNot a test of Teriparatide (PTH 1-34) aloneIn silicoOther
In simulated women with osteoporosis, TPTD/ALN yielded $46 783 in discounted per-patient costs versus $26 837 with ABL/ALN over a 10-year period.
In plain wordsIn osteoporosis simulations, TPTD/ALN yielded higher costs than ABL/ALN.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseDiscounted cost
Study
n: not reported in source
Discrete-event simulation of sequential osteoporosis treatment
Comparator
ABL/ALN
Outcome group
Cost-effectiveness · Pharmacology
Source sentences
Summary
Over a 10-year period, the DES model yielded average total discounted per-patient costs of $10 212, $46 783, and $26 837 and quality-adjusted life-years (QALYs) of 6.742, 6.781, and 6.792 for PBO/ALN, TPTD/ALN, and ABL/ALN, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
A discrete-event simulation (DES) model was developed to assess cost-effectiveness of ABL from the US health care perspective.
Summary · context
The model included three 18-month treatment strategies with either placebo (PBO), TPTD, or ABL, all followed by additional 5-year treatment with alendronate (ALN).
Summary · context
High-risk patients were defined as women with PMO ⩾65 years old with a prior vertebral fracture.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3016018602
03Computer modelNot a test of Abaloparatide (Tymlos) aloneIn silicoOther
In simulated women with osteoporosis, ABL/ALN yielded 6.792 quality-adjusted life-years versus 6.781 with TPTD/ALN over a 10-year period.
In plain wordsIn osteoporosis simulations, ABL/ALN yielded more quality-adjusted life-years than TPTD/ALN.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseQuality-adjusted life-years
Study
n: not reported in source
Discrete-event simulation of sequential osteoporosis treatment
Comparator
TPTD/ALN
Outcome group
Cost-effectiveness · Pharmacology
Source sentences
Summary
Over a 10-year period, the DES model yielded average total discounted per-patient costs of $10 212, $46 783, and $26 837 and quality-adjusted life-years (QALYs) of 6.742, 6.781, and 6.792 for PBO/ALN, TPTD/ALN, and ABL/ALN, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
A discrete-event simulation (DES) model was developed to assess cost-effectiveness of ABL from the US health care perspective.
Summary · context
The model included three 18-month treatment strategies with either placebo (PBO), TPTD, or ABL, all followed by additional 5-year treatment with alendronate (ALN).
Summary · context
High-risk patients were defined as women with PMO ⩾65 years old with a prior vertebral fracture.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3016018603
04Computer modelNot a test of Teriparatide (PTH 1-34) aloneIn silicoOther
In simulated women with osteoporosis, TPTD/ALN yielded 6.781 quality-adjusted life-years versus 6.792 with ABL/ALN over a 10-year period.
In plain wordsIn osteoporosis simulations, TPTD/ALN yielded fewer quality-adjusted life-years than ABL/ALN.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseQuality-adjusted life-years
Study
n: not reported in source
Discrete-event simulation of sequential osteoporosis treatment
Comparator
ABL/ALN
Outcome group
Cost-effectiveness · Pharmacology
Source sentences
Summary
Over a 10-year period, the DES model yielded average total discounted per-patient costs of $10 212, $46 783, and $26 837 and quality-adjusted life-years (QALYs) of 6.742, 6.781, and 6.792 for PBO/ALN, TPTD/ALN, and ABL/ALN, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
A discrete-event simulation (DES) model was developed to assess cost-effectiveness of ABL from the US health care perspective.
Summary · context
The model included three 18-month treatment strategies with either placebo (PBO), TPTD, or ABL, all followed by additional 5-year treatment with alendronate (ALN).
Summary · context
High-risk patients were defined as women with PMO ⩾65 years old with a prior vertebral fracture.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3016018604
05Computer modelNot a test of Abaloparatide (Tymlos) aloneIn silicoOther
In simulated women with osteoporosis, ABL/ALN had an ICER of $333 266/QALY relative to PBO/ALN.
In plain wordsIn computer models, ABL/ALN cost $333 266 per additional quality-adjusted life-year compared with PBO/ALN.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableIncremental cost-effectiveness ratio
Study
n: not reported in source
Discrete-event simulation of sequential osteoporosis treatment
Comparator
PBO/ALN
Outcome group
Cost-effectiveness · Pharmacology
Source sentences
Summary
Compared with TPTD/ALN, ABL/ALN accrued higher QALYs at lower cost and produced an incremental cost-effectiveness ratio (ICER) of $333 266/QALY relative to PBO/ALN.
3 context sentences(design, population, supporting numbers)
Summary · context
A discrete-event simulation (DES) model was developed to assess cost-effectiveness of ABL from the US health care perspective.
Summary · context
The model included three 18-month treatment strategies with either placebo (PBO), TPTD, or ABL, all followed by additional 5-year treatment with alendronate (ALN).
Summary · context
High-risk patients were defined as women with PMO ⩾65 years old with a prior vertebral fracture.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3016018605
06Computer modelNot a test of Abaloparatide (Tymlos) aloneIn silicoOther
In simulated high-risk women, ABL/ALN had an ICER of $188 891/QALY relative to PBO/ALN.
In plain wordsIn high-risk osteoporosis simulations, ABL/ALN cost $188 891 per additional quality-adjusted life-year compared with PBO/ALN.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableHigh-risk incremental cost-effectiveness ratio
Study
n: not reported in source
Discrete-event simulation of sequential osteoporosis treatment
Comparator
PBO/ALN
Outcome group
Cost-effectiveness · Pharmacology
Source sentences
Summary
In high-risk women, ABL/ALN also had more QALYs and less cost over TPTD/ALN and yielded an ICER of $188 891/QALY relative to PBO/ALN.
3 context sentences(design, population, supporting numbers)
Summary · context
A discrete-event simulation (DES) model was developed to assess cost-effectiveness of ABL from the US health care perspective.
Summary · context
The model included three 18-month treatment strategies with either placebo (PBO), TPTD, or ABL, all followed by additional 5-year treatment with alendronate (ALN).
Summary · context
High-risk patients were defined as women with PMO ⩾65 years old with a prior vertebral fracture.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3016018606
07Computer modelNot a test of Abaloparatide (Tymlos) aloneIn silicoOther
In simulated high-risk women, ABL/ALN yielded more QALYs than TPTD/ALN.
In plain wordsIn high-risk osteoporosis simulations, ABL/ALN yielded more quality-adjusted life-years than TPTD/ALN.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseHigh-risk quality-adjusted life-years
Study
n: not reported in source
Discrete-event simulation of sequential osteoporosis treatment
Comparator
TPTD/ALN
Outcome group
Cost-effectiveness · Pharmacology
Source sentences
Summary
In high-risk women, ABL/ALN also had more QALYs and less cost over TPTD/ALN and yielded an ICER of $188 891/QALY relative to PBO/ALN.
3 context sentences(design, population, supporting numbers)
Summary · context
A discrete-event simulation (DES) model was developed to assess cost-effectiveness of ABL from the US health care perspective.
Summary · context
The model included three 18-month treatment strategies with either placebo (PBO), TPTD, or ABL, all followed by additional 5-year treatment with alendronate (ALN).
Summary · context
High-risk patients were defined as women with PMO ⩾65 years old with a prior vertebral fracture.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3016018607
08Computer modelNot a test of Abaloparatide (Tymlos) aloneIn silicoOther
In simulated high-risk women, ABL/ALN cost less than TPTD/ALN.
In plain wordsIn high-risk osteoporosis simulations, ABL/ALN cost less than TPTD/ALN.
Peptide
Abaloparatide (Tymlos)
Outcome
DecreaseHigh-risk cost
Study
n: not reported in source
Discrete-event simulation of sequential osteoporosis treatment
Comparator
TPTD/ALN
Outcome group
Cost-effectiveness · Pharmacology
Source sentences
Summary
In high-risk women, ABL/ALN also had more QALYs and less cost over TPTD/ALN and yielded an ICER of $188 891/QALY relative to PBO/ALN.
3 context sentences(design, population, supporting numbers)
Summary · context
A discrete-event simulation (DES) model was developed to assess cost-effectiveness of ABL from the US health care perspective.
Summary · context
The model included three 18-month treatment strategies with either placebo (PBO), TPTD, or ABL, all followed by additional 5-year treatment with alendronate (ALN).
Summary · context
High-risk patients were defined as women with PMO ⩾65 years old with a prior vertebral fracture.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3016018608

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 2
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States.

Summary

Results from this study8

Studies that did not test the peptide alone8

Version history

Subjects

Publication types

MeSH terms

Keywords